No way! But... [Design Issues]

posted by wienui  – Germany/Oman, 2019-12-07 05:01 (1653 d 23:20 ago) – Posting: # 20955
Views: 6,318

(edited by wienui on 2019-12-07 06:47)

Dear all,

❝ So here two answers - theoretically there is no problem to use all data, but regulatory authorities can bann you for it. (IMHO)


I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

Best regards,
Osama

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
23,057 posts in 4,840 threads, 1,641 registered users;
116 visitors (0 registered, 116 guests [including 73 identified bots]).
Forum time: 05:21 CEST (Europe/Vienna)

If you tell the truth you don’t have to remember anything.    Mark Twain

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5